IGHA1 and IgA glomerulonephritis: Proteinuria has been shown to be an adverse prognostic factor in IgA nephropathy, with a strong relationship between proteinuria and kidney outcomes.10 During the 36-week double-blind period, atacicept also demonstrated a statistically significant reduction of serum Gd-IgA1, hematuria resolution, and preservation of eGFR.18 All participants who completed the double-blind period on study treatment were eligible for treatment with atacicept during a 60-week, open-label extension (OLE) period.